Editas Medicine
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
About
Editas Medicine harnesses the power of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases. Their goal is to discover, develop, manufacture, and commercialize transformative, durable genomic medicines for many diseases. They are motivated to deliver these transformative medicines to the greatest number of patients around the world. Teams look it up for Biotech, MedTech, Genomics.
Frequently asked
What does Editas Medicine do?
Editas Medicine is a Biotech company that offers Platform. Teams look it up for MedTech, Genomics, Drug Discovery. It is based in Cambridge, United States and was founded in 2013. Public records show about 185 people and $210M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Editas Medicine raised?
Editas Medicine has raised a total of $210M in funding. The most recent round on record is Series B.
Where is Editas Medicine headquartered?
Editas Medicine is headquartered in Cambridge, United States.
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
What industry does Editas Medicine operate in?
Editas Medicine operates in Biotech, MedTech, Genomics, Drug Discovery, Clinical Trials.
How many employees does Editas Medicine have?
Editas Medicine has approximately 185 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.